Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aaron Seth Kesselheim, M.D.


This page shows the publications co-authored by Aaron Kesselheim and Daniel Solomon.
Connection Strength

  1. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. J Gen Intern Med. 2015 Nov; 30(11):1633-8.
    View in: PubMed
    Score: 0.636
  2. Incentives for drug development--the curious case of colchicine. N Engl J Med. 2010 Jun 03; 362(22):2045-7.
    View in: PubMed
    Score: 0.450
  3. Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. Ann Intern Med. 2019 10 15; 171(8):578-579.
    View in: PubMed
    Score: 0.217
  4. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Arthritis Rheumatol. 2016 05; 68(5):1076-9.
    View in: PubMed
    Score: 0.171
  5. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
    View in: PubMed
    Score: 0.128
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.